SCHEMBL2163144

SCHEMBL2163144

COc1ccc2nc3cc(N4CCC(O)CC4)ccc3n2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
USP2 O75604 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SUV39H2 Q9H5I1 3/20 0.41
GAA P10253 2/20 0.41
GLA P06280 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NTSR1 P30989 1/20 0.39
SLC18A3 Q16572 1/20 0.38
ABL1 P00519 1/20 0.37
ENPP2 Q13822 1/20 0.37
HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2162659 0.85 KMT2A (0.37) MEN1KMT2AHPGDGAAMAPT
SCHEMBL2162800 0.81 ALK (0.38) MEN1KMT2AKDM4EALDH1A1CASP1
SCHEMBL2163138 0.76 KDM4E (0.47) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL2162795 0.74 ALK (0.38) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL3391134 0.73 SLC18A3 (0.60) MEN1KMT2AALDH1A1HSD17B10GAA
SCHEMBL24554001 0.73 NPM1 (0.49) MEN1KMT2AKDM4EALDH1A1USP2
SCHEMBL29671894 0.73 NPM1 (0.49) MEN1KMT2AKDM4EALDH1A1USP2
SCHEMBL23657145 0.70 ADRB1 (0.61) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL31648770 0.65 SLC18A3 (0.54) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL2162822 0.65 TLR9 (0.42) TLR9TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
EP-2550255-A1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS Siemens Medical Solutions USA, Inc. (US) 2013-01-30 EP disclosed
WO-2011119565-A1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-09-29 WO disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 MEN1 335/4885KMT2A 4784/4885KDM4E 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.